Skip to main content

Table 4 Predominant symptoms prior to particle radiotherapy and their relative improvement development during follow-up

From: Clinical outcome after particle therapy for meningiomas of the skull base: toxicity and local control in patients treated with active rasterscanning

 

Symptoms before particle irradiation

Symptoms at last follow-up

Clinical outcome

Predominant clinical symptomps

low grade (CTCAE I-II)

high grade (CTCAE III or higher)

low grade (CTCAE I-II)

high grade (CTCAE III or higher)

stable or improvement

worsening

 

n=

%

n=

%

n=

%

n=

%

n=

%

n=

%

visual impairment

35

31.8%

10

9.1%

28

25.5%

11

10.0%

38

34.5%

6

5.5%

headaches

35

31.8%

0

0.0%

27

24.5%

1

0.9%

46

41.8%

9

8.l2%

hearing impairment

25

22.7%

3

2.7%

25

22.7%

2

1.8%

33

30.0%

3

2.7%

motoric impairment

19

17.3%

1

0.9%

15

13.6%

2

1.8%

20

18.2%

1

0.9%

sensory impairment

14

12.7%

0

0.0%

12

10.9%

0

0.0%

16

14.5%

2

1.8%

dizziness

13

11.8%

0

0.0%

9

8.2%

0

0.0%

21

19.1%

2

1.8%

facial pain

13

11.8%

0

0.0%

9

8.2%

0

0.0%

21

19.1%

2

1.8%

cognitive impairment

11

10.0%

1

0.9%

14

12.7%

2

1.8%

16

14.5%

4

3.6%

seizures

9

8.2%

1

0.9%

2

1.8%

1

0.9%

9

8.2%

1

0.9%

fatigue

6

5.5%

0

0.0%

15

13.6%

1

0.9%

42

38.2%

8

7.3%

nausea

4

3.6%

0

0.0%

9

8,2%

0

0,0%

22

20.0%

0

0.0%

mucositis

0

0.0%

0

0.0%

1

0,9%

1

0,9%

2

1.8%

0

0.0%